Clinical trials for RD medicines are available in Canada.
Clinical trials for RD medicines are available in Canada. Agree strongly
Clinical trials for RD medicines are available in Canada. Agree
Clinical trials for RD medicines are available in Canada. Neutral
Clinical trials for RD medicines are available in Canada. Disagree
Clinical trials for RD medicines are available in Canada. Disagree Strongly
RD drugs are launched in Canada at same time as elsewhere.
RD drugs are launched in Canada at same time as elsewhere. Agree strongly
RD drugs are launched in Canada at same time as elsewhere. Agree
RD drugs are launched in Canada at same time as elsewhere. Neutral
RD drugs are launched in Canada at same time as elsewhere. Disagree
RD drugs are launched in Canada at same time as elsewhere. Disagree Strongly
Health Canada conducts timely expedited approval of RD drugs.
Health Canada conducts timely expedited approval of RD drugs. Agree strongly
Health Canada conducts timely expedited approval of RD drugs. Agree
Health Canada conducts timely expedited approval of RD drugs. Neutral
Health Canada conducts timely expedited approval of RD drugs. Disagree
Health Canada conducts timely expedited approval of RD drugs. Disagree Strongly
CADTH/INESSS make appropriate recommendations on value of RD drugs.
CADTH/INESSS make appropriate recommendations on value of RD drugs. Agree strongly
CADTH/INESSS make appropriate recommendations on value of RD drugs. Agree
CADTH/INESSS make appropriate recommendations on value of RD drugs. Neutral
CADTH/INESSS make appropriate recommendations on value of RD drugs. Disagree
CADTH/INESSS make appropriate recommendations on value of RD drugs. Disagree Strongly
Manufacturers and public drug plans complete timely negotiations for RD drugs.
Manufacturers and public drug plans complete timely negotiations for RD drugs. Agree strongly
Manufacturers and public drug plans complete timely negotiations for RD drugs. Agree
Manufacturers and public drug plans complete timely negotiations for RD drugs. Neutral
Manufacturers and public drug plans complete timely negotiations for RD drugs. Disagree
Manufacturers and public drug plans complete timely negotiations for RD drugs. Disagree Strongly
Patients who might reasonably benefit can access RD drugs.
Patients who might reasonably benefit can access RD drugs. Agree strongly
Patients who might reasonably benefit can access RD drugs. Agree
Patients who might reasonably benefit can access RD drugs. Neutral
Patients who might reasonably benefit can access RD drugs. Disagree
Patients who might reasonably benefit can access RD drugs. Disagree Strongly
Clinicians can make RD drugs available without onerous barriers.
Clinicians can make RD drugs available without onerous barriers. Agree strongly
Clinicians can make RD drugs available without onerous barriers. Agree
Clinicians can make RD drugs available without onerous barriers. Neutral
Clinicians can make RD drugs available without onerous barriers. Disagree
Clinicians can make RD drugs available without onerous barriers. Disagree Strongly
Private drug plans make RD drugs available as soon as approved by Health Canada
Private drug plans make RD drugs available as soon as approved by Health Canada Agree strongly
Private drug plans make RD drugs available as soon as approved by Health Canada Agree
Private drug plans make RD drugs available as soon as approved by Health Canada Neutral
Private drug plans make RD drugs available as soon as approved by Health Canada Disagree
Private drug plans make RD drugs available as soon as approved by Health Canada Disagree Strongly
Patient co-pays for RD drugs are not a barrier to access.
Patient co-pays for RD drugs are not a barrier to access. Agree strongly
Patient co-pays for RD drugs are not a barrier to access. Agree
Patient co-pays for RD drugs are not a barrier to access. Neutral
Patient co-pays for RD drugs are not a barrier to access. Disagree
Patient co-pays for RD drugs are not a barrier to access. Disagree Strongly
Patients participate in informed decisions about RD treatment options.
Patients participate in informed decisions about RD treatment options. Agree strongly
Patients participate in informed decisions about RD treatment options. Agree
Patients participate in informed decisions about RD treatment options. Neutral
Patients participate in informed decisions about RD treatment options. Disagree
Patients participate in informed decisions about RD treatment options. Disagree Strongly
Patients are willing to share real-world data on RD treatment outcomes.
Patients are willing to share real-world data on RD treatment outcomes. Agree strongly
Patients are willing to share real-world data on RD treatment outcomes. Agree
Patients are willing to share real-world data on RD treatment outcomes. Neutral
Patients are willing to share real-world data on RD treatment outcomes. Disagree
Patients are willing to share real-world data on RD treatment outcomes. Disagree Strongly